Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 2

Conditions

Ovarian Neoplasms 1423Uterine Cervical Neoplasms 926Endometrial Neoplasms 493Carcinoma, Ovarian Epithelial 426Breast Neoplasms 425Fallopian Tube Neoplasms 413Neoplasms 274Uterine Cervical Dysplasia 208Colorectal Neoplasms 170Carcinoma, Non-Small-Cell Lung 168Pancreatic Neoplasms 156Prostatic Neoplasms 153Lung Neoplasms 151Stomach Neoplasms 126Peritoneal Neoplasms 119Sarcoma 117Uterine Neoplasms 112Melanoma 111Urinary Bladder Neoplasms 108Papillomavirus Infections 107Colonic Neoplasms 106Head and Neck Neoplasms 105Vulvar Neoplasms 101Esophageal Neoplasms 100Recurrence 95Testicular Neoplasms 91Carcinoma, Renal Cell 89Vaginal Neoplasms 79Small Cell Lung Carcinoma 77Kidney Neoplasms 74

Interventions

Sorafenib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Recurrent Uterine Sarcoma × Gynecologic × Clear all
NCT00075400 2019-07-24

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
26 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

NCT00238121 2015-11-20

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡